Height Loss in Women: Labs, Causes, and Next Steps

Why Women Lose Height: The Core Physiology

Height loss in women is rarely one thing. It happens because the structures that hold you upright, your vertebral bones, intervertebral discs, and postural muscles, change at different rates across the lifespan. The critical point is that women are disproportionately affected compared with men, largely because of estrogen's central role in bone maintenance.

Estrogen suppresses osteoclast activity, the process by which old bone is broken down. When estrogen drops sharply at menopause, osteoclasts work faster than osteoblasts can rebuild, and net bone is lost. This imbalance is most severe in the first three to five years after the final menstrual period.

Vertebral Compression Fractures

The most clinically significant cause of height loss is a vertebral compression fracture (VCF). The thoracic and lumbar spine bear the most weight, and when bone density falls below a threshold, everyday loading, a cough, bending to lift groceries, can fracture a vertebral body. Up to two-thirds of VCFs produce no acute pain, so women often lose an inch or more before anyone investigates.

Each fractured vertebra contributes roughly 1 cm (about 0.4 inches) of height loss. A woman with three thoracic compression fractures may have lost more than an inch from fractures alone, and she may never have felt them happen.

Disc Degeneration and Loss of Hydration

Intervertebral discs lose water content progressively after age 30. This process, called disc desiccation, is not preventable entirely, but it is accelerated by smoking, sedentary behavior, and chronic low estrogen states. Disc height loss contributes approximately 30% of total age-related height reduction across the lifespan, making it a real but secondary factor compared with bone loss.

Postural Muscle Loss and Kyphosis

Sarcopenia, the progressive loss of muscle mass, reduces the ability of paraspinal muscles to hold the spine erect. The result is an increased thoracic kyphosis (a forward rounding of the upper back) that appears as both height loss and a change in posture. Women lose muscle mass faster after menopause, and low protein intake compounds this. Kyphosis from muscle loss and wedge fractures together are why the forward-bent posture is so strongly associated with late postmenopause.

How Height Loss Differs Across Your Life Stage

Reproductive Years (Ages 20 to 40)

Height loss during this period is uncommon and should prompt a search for a secondary cause. Secondary osteoporosis in premenopausal women accounts for roughly half of low bone density cases in this age group and is driven by conditions such as PCOS with hypothalamic dysfunction, amenorrhea (athletic triad or disordered eating), hyperthyroidism, celiac disease, inflammatory bowel disease, or long-term glucocorticoid use.

If you are under 40 and noticing height loss or have a DXA showing a Z-score below -2.0, a secondary cause is more likely than primary osteoporosis.

Trying to Conceive and Pregnancy

Pregnancy itself causes modest, temporary changes in spinal loading due to the relaxin effect on ligaments. True height loss from bone fracture during pregnancy is rare but reported in women with pre-existing osteoporosis, severe vitamin D deficiency, or a history of prolonged amenorrhea.

Pregnancy-associated osteoporosis (PAO) is a rare condition, most often presenting in the third trimester or early postpartum, with severe back pain and confirmed vertebral fractures. PAO occurs in approximately 1 in 500,000 pregnancies but is likely underdiagnosed. Any woman with acute back pain and height loss during or just after pregnancy deserves spinal imaging and a bone health referral.

Postpartum and Lactation

Lactation draws heavily on maternal calcium stores. Bone mineral density at the lumbar spine can fall 3 to 5% during six months of breastfeeding, driven by elevated PTHrP from the breast, which suppresses ovarian estrogen and mobilizes skeletal calcium. The reassuring news is that this bone loss reverses almost completely within six to twelve months of weaning in women with adequate calcium and vitamin D intake. Routine DXA during lactation is not indicated unless there is pain, fracture, or a known high-risk history.

Perimenopause (Ages 40 to 51 on Average)

This is the window where bone loss begins accelerating, often years before the final menstrual period. FSH starts rising while estradiol fluctuates, and the net effect on bone is negative even when cycles are still irregular rather than absent. The Study of Women's Health Across the Nation (SWAN) showed that lumbar spine bone mineral density declined by an average of 2.5% in the two years around the final menstrual period. Women who enter perimenopause with lower baseline density, common in Asian and White women, have less reserve before reaching the fracture threshold.

Height measurement at every perimenopause visit is a simple screening tool that costs nothing.

Postmenopause

The postmenopausal period carries the highest absolute risk of both osteoporosis and VCF. One in two women over age 50 will sustain an osteoporosis-related fracture in her lifetime, compared with one in four men. The decade immediately after menopause is when most bone is lost and when height surveillance matters most. Any loss exceeding 1.5 inches (3.8 cm) from peak adult height, or 0.8 inches (2 cm) in the last one to three years, is an indication for vertebral imaging regardless of DXA result.

Labs to Order: A Targeted Workup for Height Loss

Height loss is not simply a bone density question. The goal of the initial workup is to identify modifiable causes of bone loss, rule out secondary causes, and quantify fracture risk.

First-Line Labs

The following panel covers the most common and treatable contributors:

• 25-hydroxyvitamin D: Target is 30 to 50 ng/mL for bone health. Levels below 20 ng/mL impair calcium absorption and accelerate secondary hyperparathyroidism.
• Serum calcium (total and ionized) and albumin: Hypercalcemia suggests primary hyperparathyroidism; hypocalcemia may reflect malabsorption or severe vitamin D deficiency.
• Intact PTH: Elevated PTH with normal or low calcium points to vitamin D deficiency or malabsorption. Elevated PTH with high calcium suggests primary hyperparathyroidism, a known secondary cause of osteoporosis.
• TSH: Both overt and subclinical hyperthyroidism accelerate bone resorption. Women taking levothyroxine for hypothyroidism who are over-suppressed have significantly higher fracture risk.
• CBC: Anemia may suggest multiple myeloma or celiac disease.
• Comprehensive metabolic panel (CMP): Renal function affects vitamin D activation; liver disease impairs vitamin D metabolism; elevated alkaline phosphatase may signal Paget disease.
• 24-hour urine calcium and creatinine: Hypercalciuria is a common, reversible contributor to bone loss and is found in up to 20% of women with osteoporosis.

Bone Turnover Markers

Two markers give real-time information about the rate of bone remodeling:

• Serum CTX (C-terminal telopeptide): A marker of bone resorption. Elevated values confirm active bone loss and help monitor response to antiresorptive therapy within three to six months of starting treatment.
• P1NP (procollagen type 1 N-terminal propeptide): A marker of bone formation. The IOF and ISCD recommend CTX and P1NP as the reference bone turnover markers for clinical practice.

Bone turnover markers are most useful when collected fasting and in the morning, because they follow a diurnal rhythm.

When to Add More Tests

If the first-line panel is inconclusive or clinical suspicion for a secondary cause is high, add:

• Serum protein electrophoresis (SPEP) and free light chains: To screen for multiple myeloma, especially in women over 65 with unexplained bone loss.
• Celiac antibodies (tTG-IgA and total IgA): Celiac disease causes malabsorption of calcium and vitamin D and is twice as common in women as in men.
• Serum cortisol or 24-hour urine free cortisol: If Cushing syndrome is suspected (central weight gain, purple striae, easy bruising).
• Testosterone and DHEA-S: Low androgens in premenopausal women, including those with hypothalamic amenorrhea, contribute to bone loss.
• FSH and estradiol: To confirm postmenopausal status or document hypoestrogenic states in younger women.

Imaging: Beyond the DXA

DXA Scan

Dual-energy X-ray absorptiometry (DXA) of the lumbar spine and hip remains the standard for measuring bone mineral density. A T-score at or below -2.5 meets the WHO definition of osteoporosis; between -1.0 and -2.5 is osteopenia. The National Osteoporosis Foundation and USPSTF recommend DXA screening for all women age 65 and older, and earlier if a younger woman has clinical risk factors.

A normal DXA does not rule out fracture. Up to 30% of women who sustain a vertebral fracture have a DXA T-score above -2.5. This is why height measurement is essential alongside density.

Vertebral Fracture Assessment (VFA)

VFA is a low-radiation lateral spine image acquired during the DXA scan itself. It identifies vertebral deformities and compression fractures that would otherwise go undetected. The International Society for Clinical Densitometry (ISCD) recommends VFA when height loss exceeds 1.5 inches (4 cm) from peak height, when there is historical height loss of 0.8 inches (2 cm), or when a woman has back pain with risk factors for fracture.

Lateral Spine X-Ray

A plain lateral thoracic and lumbar spine X-ray identifies vertebral compression fractures with high accuracy and is a reasonable alternative when VFA is not available. A Genant Grade 1 fracture (20 to 25% vertebral height loss) is often missed on clinical examination but detectable on imaging.

FRAX Score

FRAX is not imaging, but it belongs in every height-loss workup. The Fracture Risk Assessment Tool calculates your ten-year probability of a major osteoporotic fracture and hip fracture using clinical variables. FRAX is calibrated for sex, and female sex is an independent risk factor in the model. A FRAX hip fracture probability above 3% or major fracture probability above 20% is the threshold used by most U.S. Guidelines to initiate pharmacologic therapy.

Treatment Options by Life Stage and Severity

Foundational Measures for All Women

Before any medication, optimize the basics.

• Calcium: The recommended dietary intake is 1,000 mg/day for women aged 19 to 50 and 1,200 mg/day for women over 50. Food sources are preferred. Supplements above 500 mg at a single dose are less well absorbed and may carry cardiovascular risk signals in some observational data, though randomized trial data remain inconclusive.
• Vitamin D: Most guidelines support a target of 1,500 to 2,000 IU/day of vitamin D3 for women at risk of deficiency. Test before supplementing at higher doses.
• Weight-bearing exercise: Resistance training and impact exercise (brisk walking, dancing) have small but consistent effects on bone mineral density at the lumbar spine. Aim for two to three sessions per week.
• Fall prevention: Sarcopenia, peripheral neuropathy, and psychotropic medications increase fall risk. A physical therapy referral for balance training reduces fracture risk independently of bone density.

Antiresorptive Therapy

Bisphosphonates (alendronate, risedronate, zoledronic acid, ibandronate) are the most prescribed first-line agents for postmenopausal osteoporosis. Alendronate 70 mg weekly reduces vertebral fracture risk by approximately 47% over three years in women with osteoporosis (Fracture Intervention Trial). Zoledronic acid 5 mg IV once yearly is an option for women who cannot tolerate oral bisphosphonates.

Denosumab (60 mg SC every six months) is a RANK-L inhibitor that reduces vertebral fracture risk by 68% over three years compared with placebo, per the FREEDOM trial. It is especially useful in women with renal impairment, where bisphosphonates are contraindicated. A critical caveat: denosumab must not be discontinued without a transition plan, because rebound bone loss can be severe and rapid.

Anabolic Therapy

For women with severe osteoporosis (multiple fractures, T-score below -3.0, or fracture despite antiresorptive therapy), anabolic agents build new bone rather than simply slowing loss.

• Teriparatide (Forteo) 20 mcg SC daily and abaloparatide (Tymlos) 80 mcg SC daily are PTH analogs approved for up to 24 months. Teriparatide reduced new vertebral fractures by 65% in the key trial.
• Romosozumab (Evenity) 210 mg SC monthly for 12 months is a sclerostin inhibitor with both anabolic and antiresorptive effects. It carries an FDA boxed warning for cardiovascular events and is contraindicated in women with a history of myocardial infarction or stroke in the prior year.

Hormone Therapy in Perimenopausal and Early Postmenopausal Women

Estrogen-containing hormone therapy (HT) is approved for the prevention of osteoporosis in postmenopausal women and is particularly appropriate for women who are also managing vasomotor symptoms, genitourinary syndrome of menopause (GSM), or sexual health concerns. The Women's Health Initiative showed that combined estrogen-progestin HT reduced hip fracture risk by 33% and vertebral fracture risk by 34% compared with placebo. Bone protection persists only as long as HT is continued.

The Menopause Society (formerly NAMS) supports the use of hormone therapy for bone protection in women under 60 or within ten years of menopause onset, provided there are no contraindications. This is an individualized conversation, not a blanket recommendation.

A practical decision framework for height-loss evaluation and treatment timing in women, organized by life stage and height-loss magnitude, fills a gap that existing clinical tools (FRAX, ISCD position statements) address only partially. The table below integrates these inputs into a single triage structure:

| Life Stage | Height Loss Threshold for Action | First Step | When to Medicate | |---|---|---|---| | Reproductive years | Any measurable loss + symptoms | Labs, rule out secondary causes | If T-score <-2.0 plus secondary cause or fragility fracture | | Perimenopause | >0.5 in (1.3 cm) | Height measurement every visit, DXA if loss confirmed | T-score <-2.5 or FRAX threshold | | Early postmenopause | >0.8 in (2 cm) in 1-3 yrs | VFA or spine X-ray plus DXA | FRAX threshold or confirmed VCF | | Late postmenopause | Any new loss or acute back pain | Urgent spine imaging | Confirmed fracture: anabolic preferred |

Who This Is Right For, and Who Should Wait

Height loss workup is appropriate for:

• Any woman who measures at least 1.5 inches shorter than her peak adult height
• Any woman with new acute or subacute back pain and known osteopenia or osteoporosis
• Premenopausal women with amenorrhea lasting more than six months, a fragility fracture, or a secondary condition known to affect bone (celiac disease, inflammatory bowel disease, glucocorticoid use)
• Women in perimenopause with additional risk factors: family history of hip fracture, low body weight (BMI <20), smoking, alcohol use above two drinks per day, or prior fragility fracture

Watchful waiting without imaging is acceptable for:

• A woman with height loss well under one inch, no back pain, no risk factors, and a recent normal DXA
• A postpartum woman who is breastfeeding and has no history of fracture or pre-existing bone disease

The distinction matters because over-testing has its own costs, including incidental findings, radiation, and anxiety.

Conditions That Make Height Loss More Likely in Women

Several female-specific and female-predominant conditions raise baseline risk:

• PCOS: Women with PCOS who have oligo-ovulation or hypothalamic amenorrhea experience prolonged low-estrogen intervals. However, the hyperandrogenism in classic PCOS may be partially bone-protective, so the net effect depends on the PCOS phenotype.
• Endometriosis treated with GnRH agonists: Leuprolide and similar agents suppress estrogen profoundly. Add-back therapy with low-dose estrogen and progestin is recommended to protect bone during GnRH agonist treatment beyond six months.
• Premature ovarian insufficiency (POI): Women diagnosed with POI before age 40 face decades of low estrogen and have substantially higher lifetime fracture risk than women with natural menopause. Hormone therapy is recommended until at least age 51 unless contraindicated.
• Female athlete triad / relative energy deficiency in sport (RED-S): Low energy availability suppresses the hypothalamic-pituitary-ovarian axis, reducing estrogen and impairing bone accrual in young athletes. Bone stress injuries and low bone density in this population are well-documented.
• Thyroid disease: Treated and untreated hyperthyroidism, as well as iatrogenic TSH suppression in thyroid cancer survivors, accelerate bone turnover in women.
• Celiac disease: Malabsorption of calcium and vitamin D, combined with inflammation, causes bone loss even in women without gastrointestinal symptoms.

Pregnancy and Lactation: Specific Safety Considerations

This section is required for completeness, because some women who discover height loss are also pregnant, recently postpartum, or planning pregnancy.

During pregnancy: Do not start bisphosphonates, denosumab, teriparatide, abaloparatide, or romosozumab in pregnancy. All of these agents are contraindicated. Bisphosphonates accumulate in bone for years and have been detected in fetal bone in animal studies; human data are limited. The FDA classifies bisphosphonates as Category C (old system) or notes insufficient human data under the current Pregnancy and Lactation Labeling Rule. Women of reproductive age taking bisphosphonates should use reliable contraception and discuss the timing of discontinuation with their provider before attempting pregnancy.

During lactation: Bisphosphonates and denosumab transfer into breast milk in animal models; human transfer data are sparse. Given that lactation-related bone loss is physiologic and largely reversible, pharmacologic intervention is almost never appropriate during breastfeeding. Prioritize calcium (1,000 mg/day) and vitamin D (1,500 to 2,000 IU/day) supplementation. DXA is deferred until after weaning unless there is a confirmed fracture.

After weaning: Bone density monitoring by DXA is reasonable six to twelve months after weaning in women who had pregnancy-associated osteoporosis, a known fragility fracture, or pre-existing bone disease. Most women with lactation-related bone loss will show complete recovery by this point.

Practical Next Steps: What to Ask Your Clinician

If you have noticed height loss, these are the four things to do before or at your next appointment:

1. Measure your height accurately (shoes off, back against a wall, head level) and compare it with your driver's license height or any prior recorded measurement.
2. Request the first-line lab panel described above, specifically 25-hydroxyvitamin D, calcium, PTH, TSH, CBC, and CMP.
3. Ask whether a DXA scan is indicated based on your age, life stage, and risk factors. If height loss exceeds 1.5 inches from peak, ask specifically about adding a VFA or lateral spine X-ray.
4. Calculate or ask your provider to calculate your FRAX score, which takes about two minutes and directly informs whether medication is warranted.

A single lateral spine X-ray identifies 30 to 40% more vertebral fractures than DXA alone in women with osteopenia, which is why imaging the spine directly matters when height loss is the presenting symptom.